10-Q: CEL-SCI Reports Q3 2025 Results, Advances Multikine Study

CEL-SCI Corporation reported a reduced net loss for the nine months ended June 30, 2025, while advancing its Multikine immunotherapy toward a confirmatory registration study despite ongoing liquidity concerns.

Summary

• CEL-SCI Corporation reported a net loss of $19.31 million for the nine months ended June 30, 2025, an improvement from $20.81 million in the prior year period.
• Net loss per common share significantly improved to $6.34 for the nine months ended June 30, 2025, compared to $12.51 for the same period in 2024, reflecting the impact of a 1-for-30 reverse stock split effective May 20, 2025.
• Research and development expenses decreased by 11% to $12.18 million for the nine months ended June 30, 2025, primarily due to lower employee stock compensation expense.
• Cash and cash equivalents decreased to $1.79 million as of June 30, 2025, from $4.74 million at September 30, 2024.
• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and future liquidity needs.
• Multikine, an investigational immunotherapy for head and neck cancers, showed a 73% survival rate at 5 years in its target patient population (low PD-L1, no lymph node involvement) in the Phase III study, compared to 45% in the control group.
• The FDA has indicated CEL-SCI may proceed with a 212-patient randomized controlled confirmatory registration study for Multikine in the target population.
• The estimated cost for the confirmatory registration study is approximately $30 million.
• The company raised approximately $11.0 million in net proceeds from common stock and pre-funded warrant offerings in December 2024, March 2025, and May 2025.
• Subsequent to the quarter end, on July 14, 2025, the company sold an additional 1,500,000 shares of common stock for gross proceeds of approximately $5.7 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to highly compelling Phase III clinical data for Multikine, a clear FDA pathway for a confirmatory study, and its unique positioning in an underserved market segment. However, this is significantly tempered by severe financial distress, including a 'going concern' warning, rapidly depleting cash reserves, and a continuous, substantial need for further capital raises, which introduce high investment risk.

Positives

• Net loss decreased to $19.31 million for the nine months ended June 30, 2025, from $20.81 million in the prior year.
• Net loss per common share significantly improved to $6.34, down from $12.51 in the prior year, partly due to the reverse stock split.
• Multikine demonstrated a 73% survival rate at 5 years in its target patient population in the Phase III study, compared to 45% in the control group, indicating a substantial survival benefit.
• The Phase III study showed a 66% reduction in the risk of death (hazard ratio 0.34) for Multikine-treated patients with low to zero PD-L1 tumor expression.
• No demonstrable safety signals or toxicities were observed in approximately 740 Multikine-treated subjects across multiple clinical trials, with no Multikine-related deaths or delays to surgery.
• The FDA has given a positive indication for CEL-SCI to move forward with a 212-patient confirmatory registration study for Multikine, providing a clear regulatory pathway.
• Multikine targets a patient population (low PD-L1 expression) that is underserved by currently available immunotherapies like Keytruda and Opdivo, addressing a significant unmet medical need.
• The company successfully raised approximately $11.0 million in net proceeds from equity offerings during the nine months ended June 30, 2025, and an additional $5.7 million gross in July 2025.

Negatives

• The company incurred a net loss of $19.31 million for the nine months ended June 30, 2025, and continues to experience recurring losses from operations.
• Cash and cash equivalents significantly decreased to $1.79 million as of June 30, 2025, from $4.74 million at September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and future liquidity needs.
• The company will be required to raise additional capital, estimated at $30 million for the confirmatory study, with no assurance of obtaining funds on a timely basis or acceptable terms.
• Disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses identified in the prior annual report.
• Total stockholders' equity decreased significantly to $7.02 million at June 30, 2025, from $12.87 million at September 30, 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and future liquidity needs.
• The company requires significant additional capital (estimated $30 million for the confirmatory study) and there is no assurance that it will be able to raise these funds on a timely basis or on acceptable terms.
• The ability to obtain marketing approval from the FDA and comparable foreign agencies for Multikine or other product candidates is uncertain.
• The company's disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses, which could impact financial reporting reliability.
• Clinical trials and research programs are dependent on available capital and regulatory approvals; inability to conduct them will prevent product development and regulatory approval.
• The company is dependent on the proceeds from the sale of its securities to meet capital requirements and anticipates this will continue in the future.

Future Outlook

The company plans to raise additional capital, estimated at $30 million, to fund the 212-patient confirmatory registration study for Multikine. They anticipate full enrollment for this study approximately 15 months after securing the necessary capital, with the potential to seek early approval after full enrollment. The company believes the confirmatory study has a high likelihood of success based on the significant survival benefit observed in the completed Phase III study's target population. They also continue to evaluate the impact of new accounting pronouncements and the recently enacted One Big Beautiful Bill Act on their financial statements.

Management Comments

• "The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer."
• "CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is given first, right after diagnosis, before any other treatment including surgery."
• "CEL-SCI believes Multikine leads to longer survival with no safety issues."
• "CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial."
• "CEL-SCI's regulatory strategy going forward is to seek approval of Multikine following full enrollment of its confirmatory study wherever possible."
• "CEL-SCI's goal is to begin the 212-patient confirmatory registration study as soon as the needed capital has been raised, with full enrollment about 15 months later with the potential to seek early approval after full enrollment."

Industry Context

The global cancer immunotherapy market is projected to reach $196.45 billion by 2030, growing at a CAGR of 7.2%. CEL-SCI aims to enter this market with Multikine, which is positioned as a first-line, pre-surgical treatment for head and neck cancer, differentiating it from existing immunotherapies like checkpoint inhibitors (e.g., Keytruda, Opdivo) that are typically given after surgery or for patients with high PD-L1 expression. Multikine specifically targets patients with low PD-L1 tumor expression, addressing an underserved segment of the market.

Comparison to Industry Standards

• Multikine is administered as a first-line treatment before standard of care (surgery), contrasting with checkpoint inhibitors like Keytruda and Opdivo which are typically given after surgery or where surgery is not indicated.
• Multikine's target population is patients with low PD-L1 tumor expression (TPS<10), which differentiates it from Keytruda and Opdivo, which appear to work best in patients with high PD-L1 expression (TPS>20 to TPS>50).
• In its Phase 3 study, Multikine reduced the risk of death by 66% and extended 5-year overall survival to 73% compared to 45% in the standard of care group for its target population.
• In contrast, Merck's Phase 3 KEYNOTE-689 trial for Keytruda in resectable locally advanced head and neck cancer patients (PD-L1 CPS ≥1) reduced the risk of recurrence and progression by 30% but did not show an improvement in overall survival.
• Multikine's observed 28.6% absolute 5-year overall survival benefit (p=0.0015) and hazard ratio of 0.35 (95% CIs [0.19, 0.66]) in its target population are strong indicators of efficacy, especially when compared to other therapies that may not demonstrate overall survival benefits in similar settings.

Corporate Governance

Related Party Transactions

• On May 4, 2024, the company modified the terms of Series UU, X, Y, N, MM, NN, and RR warrants by extending their expiration dates by 24 months. These warrants are held by current officers (Geert Kersten, Patricia Prichep) and a trust of which the CEO is a beneficiary. The incremental cost of this extension was approximately $0.7 million, recorded as a deemed dividend.
• On July 25, 2025 (subsequent event), the CEO and a director purchased 32,116 shares of restricted common stock at an aggregate fair market value of approximately $219,995.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises. The reverse stock split impacted share count but not ownership percentage. The 'going concern' warning poses a substantial risk to investment value. Positive clinical data offers potential for future value appreciation if regulatory approval and commercialization are achieved.
• **Employees**: Share-based compensation is a significant component of compensation. The company's financial instability and 'going concern' status could create job insecurity.
• **Customers (Future)**: If Multikine receives regulatory approval, it could offer a novel and effective pre-surgical treatment option for a specific subset of head and neck cancer patients, addressing an unmet medical need.
• **Creditors**: The 'going concern' warning and reliance on future capital raises indicate elevated credit risk.
• **Suppliers/CROs**: The company's financial position and need for capital could impact its ability to meet payment obligations for ongoing research and development services.

Next Steps

• Raise approximately $30 million in additional capital to fund the confirmatory registration study for Multikine.
• Initiate the 212-patient randomized controlled confirmatory registration study for Multikine.
• Achieve full enrollment for the confirmatory study, anticipated approximately 15 months after capital is raised.
• Potentially seek early approval for Multikine after full enrollment of the confirmatory study.
• Continue to evaluate the impact of new accounting pronouncements (ASU 2023-07, ASU 2023-09, ASU 2024-03) and the One Big Beautiful Bill Act on financial disclosures and statements.

Key Dates

Recommendation

While Multikine's Phase III clinical data presents a compelling case for its efficacy and safety in a specific, underserved patient population, and the FDA pathway for a confirmatory study is clear, the company's severe financial instability is a major concern. The 'going concern' warning, rapidly depleting cash reserves, and continuous reliance on dilutive capital raises create substantial risk. A seasoned investor would recognize the high-risk, high-reward profile. The strong clinical upside is currently offset by significant financial downside and operational control weaknesses. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor the company's progress in securing the necessary $30 million for the confirmatory study and addressing its liquidity issues before considering further investment, despite the promising clinical results.

Keywords

Immunotherapy, Head and Neck Cancer, Multikine, Biotechnology, Clinical Trials, Oncology, Phase 3 Study, FDA Approval, Drug Development, Going Concern, Capital Raise, PD-L1